Legal and financial questions of Pfizer-Novo-Metsera
Shareholder Primacy
00:00
What Was Novo’s Two‑Part Workaround Plan?
Mike outlines Novo's scheme to pay cash up front, take non‑voting economic interest, then seek regulatory approval for the back‑end merger.
Play episode from 10:03
Transcript
